- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00977574
Paclitaxel, carboplatine et bevacizumab ou paclitaxel, carboplatine et temsirolimus ou ixabepilone, carboplatine et bevacizumab dans le traitement des patientes atteintes d'un cancer de l'endomètre de stade III, de stade IV ou récurrent
Une étude de phase II randomisée à trois bras portant sur le paclitaxel/carboplatine/bévacizumab (NSC #704865), le paclitaxel/carboplatine/temsirolimus (NSC #683864) et l'ixabépilone (NSC #710428)/carboplatine/bévacizumab en tant que traitement initial du stade III ou IVA mesurable, Stade IVB ou cancer de l'endomètre récurrent
This randomized phase II trial studies paclitaxel, carboplatin, and bevacizumab or paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab to see how well they work in treating patients with stage III, stage IV, or recurrent endometrial cancer. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known which treatment regimen is most effective in treating patients with endometrial cancer.
Aperçu de l'étude
Statut
Les conditions
- Adénocarcinome à cellules claires de l'endomètre
- Adénocarcinome séreux de l'endomètre
- Adénocarcinome de l'endomètre
- Carcinome adénosquameux de l'endomètre
- Néoplasme de corpus utérin malin récurrent
- Étape IIIA Carcinome ou carcinosarcome du corpus utérin par étape AJCC V7
- Étape IIIB Corpus utérin Corpus ou carcinosarcome par AJCC V7 Stage
- Carcinome ou carcinosarcome du corpus utérin ou carcinosarcome par AJCC V7 Stage
- Étape Iva Uterrin Corpus Carcinome ou Carcinosarcome par AJCC V7 Stage
- Étape IVB Corpus utérin Corpus ou carcinosarcome par AJCC V7 Stage
Description détaillée
PRIMARY OBJECTIVES:
I. To estimate the hazard of progression or death of each of the three arms relative to that of historical controls in patients with advanced or recurrent endometrial cancer.
SECONDARY OBJECTIVES:
I. To determine the nature, frequency, and maximum degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v)3.0 for each of the three arms.
II. To estimate the distribution of the duration of overall survival for each of the three arms.
III. To estimate the proportion of patients with measurable disease who have confirmed objective tumor responses by treatment.
TERTIARY OBJECTIVES:
I. Explore the associations between select biomarkers and progression-free survival as well as secondary measures of clinical outcome (overall survival, tumor response, or disease status if possible) in the context of histologic cell type and treatment.
IA. Somatic mutations in phosphatase and tensin homolog (PTEN)/ phosphoinositide-3-kinase (PI3K) and RAS pathway members by Sequenom mutational profiling and targeted sequencing of candidate genes.
IB. Microsatellite instability by analysis of five National Cancer Institute consensus microsatellite markers (BAT25, BAT26, D2S2123, D5S346, and D17S250) using the Applied Biosystems (ABI) Prism 3100 Genetic Analyzer.
IC. Copy number alterations (gains or losses) by array comparative genomic hybridization (aCGH).
ID. Tumor expression of PTEN and class III beta-tubulin using immunohistochemistry.
IE. Concentration of vascular endothelial growth factor (VEGF) in pre-cycle 1 plasma using an enzyme-linked immunosorbent assay.
II. Explore the relationship among the various biomarkers by histologic subtype and treatment.
III. Explore which combination of biomarkers and clinical covariates optimally predicts responsiveness and resistance to the three treatment arms.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours, carboplatin IV over 30 minutes, and bevacizumab* IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive bevacizumab beginning on course 2.
ARM II: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus* IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive temsirolimus IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive temsirolimus beginning on course 2.
ARM III: Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and bevacizumab* IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive bevacizumab beginning on course 2.
After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85013
- Saint Joseph's Hospital and Medical Center
-
Scottsdale, Arizona, États-Unis, 85259
- Mayo Clinic in Arizona
-
Tucson, Arizona, États-Unis, 85719
- University of Arizona Cancer Center-North Campus
-
-
California
-
Burbank, California, États-Unis, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Concord, California, États-Unis, 94520
- John Muir Medical Center-Concord
-
La Jolla, California, États-Unis, 92093
- UC San Diego Moores Cancer Center
-
Los Angeles, California, États-Unis, 90095
- UCLA / Jonsson Comprehensive Cancer Center
-
Mountain View, California, États-Unis, 94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
San Diego, California, États-Unis, 92103
- UC San Diego Medical Center - Hillcrest
-
San Diego, California, États-Unis, 92161
- San Diego VA Medical Center
-
San Francisco, California, États-Unis, 94115
- UCSF Medical Center-Mount Zion
-
Walnut Creek, California, États-Unis, 94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- UCHealth University of Colorado Hospital
-
Englewood, Colorado, États-Unis, 80110
- Rocky Mountain Gynecologic Oncology PC
-
-
Connecticut
-
Hartford, Connecticut, États-Unis, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
Hartford, Connecticut, États-Unis, 06102
- Hartford Hospital
-
New Britain, Connecticut, États-Unis, 06050
- The Hospital of Central Connecticut
-
New Haven, Connecticut, États-Unis, 06520
- Yale University
-
-
Delaware
-
Lewes, Delaware, États-Unis, 19958
- Beebe Medical Center
-
Newark, Delaware, États-Unis, 19718
- Christiana Care Health System-Christiana Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Clearwater, Florida, États-Unis, 33756
- Morton Plant Hospital
-
Jacksonville, Florida, États-Unis, 32224-9980
- Mayo Clinic in Florida
-
Miami, Florida, États-Unis, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Orlando, Florida, États-Unis, 32806
- Orlando Health Cancer Institute
-
Orlando, Florida, États-Unis, 32803
- AdventHealth Orlando
-
-
Georgia
-
Macon, Georgia, États-Unis, 31201
- Central Georgia Gynecologic Oncology
-
Savannah, Georgia, États-Unis, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, États-Unis, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, États-Unis, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, États-Unis, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, États-Unis, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, États-Unis, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, États-Unis, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, États-Unis, 96826
- Kapiolani Medical Center for Women and Children
-
Lihue, Hawaii, États-Unis, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
Wailuku, Hawaii, États-Unis, 96793
- Maui Memorial Medical Center
-
Wailuku, Hawaii, États-Unis, 96793
- Pacific Cancer Institute of Maui
-
‘Aiea, Hawaii, États-Unis, 96701
- Pali Momi Medical Center
-
-
Idaho
-
Boise, Idaho, États-Unis, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Northwestern University
-
Chicago, Illinois, États-Unis, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, États-Unis, 60612
- Rush MD Anderson Cancer Center
-
Elgin, Illinois, États-Unis, 60123
- Advocate Sherman Hospital
-
Hinsdale, Illinois, États-Unis, 60521
- Hinsdale Hematology Oncology Associates Incorporated
-
Hinsdale, Illinois, États-Unis, 60521
- Sudarshan K Sharma MD Limited-Gynecologic Oncology
-
-
Indiana
-
Elkhart, Indiana, États-Unis, 46515
- Elkhart General Hospital
-
Elkhart, Indiana, États-Unis, 46514
- Michiana Hematology Oncology PC-Elkhart
-
Elkhart, Indiana, États-Unis, 46514-2098
- Elkhart Clinic
-
Indianapolis, Indiana, États-Unis, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
Kokomo, Indiana, États-Unis, 46904
- Community Howard Regional Health
-
La Porte, Indiana, États-Unis, 46350
- IU Health La Porte Hospital
-
Mishawaka, Indiana, États-Unis, 46545
- Michiana Hematology Oncology PC-Mishawaka
-
Mishawaka, Indiana, États-Unis, 46545
- Saint Joseph Regional Medical Center-Mishawaka
-
Plymouth, Indiana, États-Unis, 46563
- Michiana Hematology Oncology PC-Plymouth
-
South Bend, Indiana, États-Unis, 46601
- Memorial Hospital of South Bend
-
South Bend, Indiana, États-Unis, 46628
- Northern Indiana Cancer Research Consortium
-
South Bend, Indiana, États-Unis, 46617
- South Bend Clinic
-
Westville, Indiana, États-Unis, 46391
- Michiana Hematology Oncology PC-Westville
-
-
Iowa
-
Ames, Iowa, États-Unis, 50010
- McFarland Clinic - Ames
-
Clive, Iowa, États-Unis, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, États-Unis, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, États-Unis, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, États-Unis, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, États-Unis, 50316
- Iowa Lutheran Hospital
-
Des Moines, Iowa, États-Unis, 50309
- Iowa-Wide Oncology Research Coalition NCORP
-
Des Moines, Iowa, États-Unis, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, États-Unis, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, États-Unis, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, États-Unis, 50266-7700
- Methodist West Hospital
-
West Des Moines, Iowa, États-Unis, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Chanute, Kansas, États-Unis, 66720
- Cancer Center of Kansas - Chanute
-
Dodge City, Kansas, États-Unis, 67801
- Cancer Center of Kansas - Dodge City
-
El Dorado, Kansas, États-Unis, 67042
- Cancer Center of Kansas - El Dorado
-
Fort Scott, Kansas, États-Unis, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, États-Unis, 67301
- Cancer Center of Kansas-Independence
-
Kansas City, Kansas, États-Unis, 66160
- University of Kansas Cancer Center
-
Kingman, Kansas, États-Unis, 67068
- Cancer Center of Kansas-Kingman
-
Lawrence, Kansas, États-Unis, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, États-Unis, 67905
- Cancer Center of Kansas-Liberal
-
McPherson, Kansas, États-Unis, 67460
- Cancer Center of Kansas - McPherson
-
Newton, Kansas, États-Unis, 67114
- Cancer Center of Kansas - Newton
-
Parsons, Kansas, États-Unis, 67357
- Cancer Center of Kansas - Parsons
-
Pratt, Kansas, États-Unis, 67124
- Cancer Center of Kansas - Pratt
-
Salina, Kansas, États-Unis, 67401
- Cancer Center of Kansas - Salina
-
Wellington, Kansas, États-Unis, 67152
- Cancer Center of Kansas - Wellington
-
Wichita, Kansas, États-Unis, 67214
- Ascension Via Christi Hospitals Wichita
-
Wichita, Kansas, États-Unis, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, États-Unis, 67214
- Cancer Center of Kansas - Wichita
-
Wichita, Kansas, États-Unis, 67208
- Associates In Womens Health
-
Wichita, Kansas, États-Unis, 67214
- Wichita NCI Community Oncology Research Program
-
Winfield, Kansas, États-Unis, 67156
- Cancer Center of Kansas - Winfield
-
-
Kentucky
-
Lexington, Kentucky, États-Unis, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, États-Unis, 40503
- Baptist Health Lexington
-
Louisville, Kentucky, États-Unis, 40202
- The James Graham Brown Cancer Center at University of Louisville
-
-
Maine
-
Portland, Maine, États-Unis, 04102
- MaineHealth Maine Medical Center - Portland
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21237
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
-
Baltimore, Maryland, États-Unis, 21215
- Sinai Hospital of Baltimore
-
Baltimore, Maryland, États-Unis, 21204
- Greater Baltimore Medical Center
-
Elkton, Maryland, États-Unis, 21921
- Christiana Care - Union Hospital
-
-
Massachusetts
-
Springfield, Massachusetts, États-Unis, 01199
- Baystate Medical Center
-
Worcester, Massachusetts, États-Unis, 01605
- UMass Memorial Medical Center - Memorial Division
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48106
- Michigan Cancer Research Consortium NCORP
-
Ann Arbor, Michigan, États-Unis, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Dearborn, Michigan, États-Unis, 48124
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, États-Unis, 48236
- Henry Ford Health Saint John Hospital
-
Flint, Michigan, États-Unis, 48532
- Genesys Regional Medical Center-West Flint Campus
-
Flint, Michigan, États-Unis, 48503
- Hurley Medical Center
-
Jackson, Michigan, États-Unis, 49201
- Allegiance Health
-
Kalamazoo, Michigan, États-Unis, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, États-Unis, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, États-Unis, 49048
- Beacon Kalamazoo
-
Lansing, Michigan, États-Unis, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, États-Unis, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Niles, Michigan, États-Unis, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Pontiac, Michigan, États-Unis, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Port Huron, Michigan, États-Unis, 48060
- Lake Huron Medical Center
-
Royal Oak, Michigan, États-Unis, 48073
- Corewell Health William Beaumont University Hospital
-
Saginaw, Michigan, États-Unis, 48601
- MyMichigan Medical Center Saginaw
-
Saint Joseph, Michigan, États-Unis, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, États-Unis, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Warren, Michigan, États-Unis, 48093
- Henry Ford Health Warren Hospital
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson, Mississippi, États-Unis, 39216
- University of Mississippi Medical Center
-
Jackson, Mississippi, États-Unis, 39216
- Saint Dominic-Jackson Memorial Hospital
-
Pascagoula, Mississippi, États-Unis, 39581
- Singing River Hospital
-
-
Missouri
-
Columbia, Missouri, États-Unis, 65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Rolla, Missouri, États-Unis, 65401
- Phelps Health Delbert Day Cancer Institute
-
Springfield, Missouri, États-Unis, 65804
- Cancer Research for the Ozarks NCORP
-
Springfield, Missouri, États-Unis, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, États-Unis, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, États-Unis, 63110
- Washington University School of Medicine
-
St Louis, Missouri, États-Unis, 63104
- SSM Health Saint Louis University Hospital
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68114
- Nebraska Methodist Hospital
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89106
- Women's Cancer Center of Nevada
-
Reno, Nevada, États-Unis, 89502
- Renown Regional Medical Center
-
Reno, Nevada, États-Unis, 89502
- Center of Hope at Renown Medical Center
-
-
New Jersey
-
Camden, New Jersey, États-Unis, 08103
- Cooper Hospital University Medical Center
-
Morristown, New Jersey, États-Unis, 07960
- Morristown Medical Center
-
Mount Holly, New Jersey, États-Unis, 08060
- Virtua Memorial
-
Newark, New Jersey, États-Unis, 07101
- Rutgers New Jersey Medical School
-
Phillipsburg, New Jersey, États-Unis, 08865
- Saint Luke's Hospital-Warren Campus
-
Summit, New Jersey, États-Unis, 07902
- Overlook Hospital
-
Voorhees Township, New Jersey, États-Unis, 08043
- Virtua Voorhees
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque, New Mexico, États-Unis, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, États-Unis, 12208
- Women's Cancer Care Associates LLC
-
Brightwaters, New York, États-Unis, 11718
- Island Gynecologic Oncology
-
Brooklyn, New York, États-Unis, 11203
- State University of New York Downstate Medical Center
-
Buffalo, New York, États-Unis, 14263
- Roswell Park Cancer Institute
-
Fresh Meadows, New York, États-Unis, 11365
- New York Hospital Medical Center of Queens
-
New York, New York, États-Unis, 10065
- Memorial Sloan Kettering Cancer Center
-
Stony Brook, New York, États-Unis, 11794
- Stony Brook University Medical Center
-
-
North Carolina
-
Asheville, North Carolina, États-Unis, 28816
- Hope Women's Cancer Centers-Asheville
-
Burlington, North Carolina, États-Unis, 27215
- Cone Health Cancer Center at Alamance Regional
-
Charlotte, North Carolina, États-Unis, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, États-Unis, 28204
- Novant Health Presbyterian Medical Center
-
Durham, North Carolina, États-Unis, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, États-Unis, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Akron, Ohio, États-Unis, 44307
- Cleveland Clinic Akron General
-
Akron, Ohio, États-Unis, 44304
- Summa Health System - Akron Campus
-
Cincinnati, Ohio, États-Unis, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, États-Unis, 44106
- Case Western Reserve University
-
Cleveland, Ohio, États-Unis, 44109
- MetroHealth Medical Center
-
Cleveland, Ohio, États-Unis, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, États-Unis, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, États-Unis, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, États-Unis, 43210
- Ohio State University Comprehensive Cancer Center
-
Dayton, Ohio, États-Unis, 45409
- Miami Valley Hospital
-
Kettering, Ohio, États-Unis, 45429
- Kettering Medical Center
-
Mayfield Heights, Ohio, États-Unis, 44124
- Hillcrest Hospital Cancer Center
-
Mentor, Ohio, États-Unis, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, États-Unis, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Pennsylvania
-
Abington, Pennsylvania, États-Unis, 19001
- Jefferson Abington Hospital
-
Allentown, Pennsylvania, États-Unis, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Danville, Pennsylvania, États-Unis, 17822
- Geisinger Medical Center
-
Hazleton, Pennsylvania, États-Unis, 18201
- Geisinger Medical Center-Cancer Center Hazleton
-
Hershey, Pennsylvania, États-Unis, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Philadelphia, Pennsylvania, États-Unis, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Pennsylvania Hospital
-
State College, Pennsylvania, États-Unis, 16801
- Geisinger Medical Group
-
West Reading, Pennsylvania, États-Unis, 19611
- Reading Hospital
-
Wilkes-Barre, Pennsylvania, États-Unis, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
Rhode Island
-
Providence, Rhode Island, États-Unis, 02905
- Women and Infants Hospital
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, États-Unis, 29210
- South Carolina Oncology Associates PA
-
-
South Dakota
-
Sioux Falls, South Dakota, États-Unis, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, États-Unis, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, États-Unis, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, États-Unis, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, États-Unis, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, États-Unis, 75390
- Clements University Hospital
-
Galveston, Texas, États-Unis, 77555-0565
- University of Texas Medical Branch
-
Houston, Texas, États-Unis, 77026-1967
- Lyndon Baines Johnson General Hospital
-
Houston, Texas, États-Unis, 77030
- UT MD Anderson Cancer Center
-
Temple, Texas, États-Unis, 76508
- Scott and White Memorial Hospital
-
-
Vermont
-
Burlington, Vermont, États-Unis, 05401
- University of Vermont Medical Center
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22908
- University of Virginia Cancer Center
-
Hampton, Virginia, États-Unis, 23666
- Virginia Oncology Associates-Hampton
-
Norfolk, Virginia, États-Unis, 23502
- Virginia Oncology Associates - Norfolk
-
Richmond, Virginia, États-Unis, 23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke, Virginia, États-Unis, 24033
- Carilion Roanoke Memorial Hospital
-
-
Washington
-
Bellingham, Washington, États-Unis, 98226
- PeaceHealth Medical Group PC
-
Everett, Washington, États-Unis, 98201
- Providence Regional Cancer Partnership
-
Mount Vernon, Washington, États-Unis, 98274
- Skagit Regional Health Cancer Care Center
-
Poulsbo, Washington, États-Unis, 98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Seattle, Washington, États-Unis, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, États-Unis, 98195
- University of Washington Medical Center - Montlake
-
Seattle, Washington, États-Unis, 98112
- Kaiser Permanente Washington
-
Seattle, Washington, États-Unis, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, États-Unis, 98109
- Fred Hutchinson Cancer Center
-
Seattle, Washington, États-Unis, 98133
- University of Washington Medical Center - Northwest
-
Sequim, Washington, États-Unis, 98384
- Olympic Medical Cancer Care Center
-
Silverdale, Washington, États-Unis, 98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Spokane, Washington, États-Unis, 99202
- Cancer Care Northwest - Spokane South
-
Spokane, Washington, États-Unis, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Tacoma, Washington, États-Unis, 98405
- MultiCare Tacoma General Hospital
-
Tacoma, Washington, États-Unis, 98405
- Saint Joseph Medical Center
-
Walla Walla, Washington, États-Unis, 99362
- Providence Saint Mary Regional Cancer Center
-
Wenatchee, Washington, États-Unis, 98801
- Wenatchee Valley Hospital and Clinics
-
-
Wisconsin
-
La Crosse, Wisconsin, États-Unis, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, États-Unis, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Milwaukee, Wisconsin, États-Unis, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, États-Unis, 53233
- Aurora Sinai Medical Center
-
Oshkosh, Wisconsin, États-Unis, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Sheboygan, Wisconsin, États-Unis, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
West Allis, Wisconsin, États-Unis, 53227
- Aurora West Allis Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Patients must have measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial carcinoma
- Histologic confirmation of the original primary tumor is required; patients with the following histologic epithelial cell types are eligible: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous cell carcinoma, and transitional cell carcinoma
-
Measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
-
Patients must have Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2
-
Patients must not be eligible for a higher priority GOG protocol, if one exists; in general, this would refer to any active GOG Phase III protocol or Rare Tumor protocol for the same patient population
-
Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl equivalent to Common Terminology Criteria (CTCAE v3.0) grade 1
-
Platelets greater than or equal to 100,000/mcl
-
Creatinine less than or equal to 1.5 times institutional upper limit normal (ULN), CTCAE v3.0 grade 1
-
Bilirubin less than or equal to 1.5 x ULN (CTCAE v3.0 grade 1)
-
Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)
-
Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)
-
Urine protein creatinine (UPC) ratio must be < 1.0 gram (gm); if UPC ratio >= 1, collection of 24-hour urine measurement of urine protein is recommended (24-hour urine protein level must be < 1000 mg for patient enrollment)
-
UPC ratio of spot urine is an estimation of the 24 urine protein excretion
- A UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm
-
-
Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) =< 1.5 x ULN
-
Fasting cholesterol less than 300 mg/dL (CTCAE v3.0 grade 1)
-
Fasting triglycerides =< 2.5 x ULN (CTCAE v3.0 grade 1)
-
Patients must NOT have received prior chemotherapy or targeted therapy, including chemotherapy used for radiation sensitization for treatment of endometrial carcinoma
-
Patients must NOT have received prior therapy with bevacizumab or other VEGF pathway targeted therapy; patients must NOT have received prior therapy with temsirolimus, everolimus, ridaforolimus, sirolimus, or any other PI3K/ v-akt murine thymoma viral oncogene homolog 1 (AKT)/mammalian target of rapamycins (mTor) pathway targeted therapy
-
Patients may have receive prior radiation therapy for treatment of endometrial carcinoma; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy; all radiation therapy must be completed at least 4 weeks prior to the first date of study therapy; the prior radiation field, radiation dose, number of fractions and prior radiation start and stop dates must be provided on the Fast Fact Sheet (FFS) at registration
-
Patients may have received prior hormonal therapy for treatment of endometrial carcinoma; all hormonal therapy must be discontinued at least one week prior to the first date of study therapy
-
Patients must have signed an approved informed consent and authorization permitting release of personal health information
Exclusion Criteria:
-
Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, and other specific malignancies as noted below, are excluded if there is any evidence of other malignancy being present within the last three years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
-
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of endometrial cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
-
Patients who have received prior chemotherapy for any abdominal or pelvic tumor within the last three years are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease
-
Patients with serious, non-healing wound, ulcer, or bone fracture; this includes history of abdominal/pelvic fistula, gastrointestinal perforation or intra-abdominal abscess within 3 months prior to the first date of study therapy; patients with underlying lesions that caused the fistula or perforation in the past that have not been corrected
-
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
-
Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy or any brain metastases
-
Patients with clinically significant cardiovascular disease; this includes:
- Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg
- Myocardial infarction or unstable angina within 6 months of the first date of study therapy
- New York Heart Association (NYHA) class II or greater congestive heart failure
- History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)
- CTCAE grade 2 or greater peripheral vascular disease.
- History of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of study therapy.
- Aortic aneurysm and/or history of aortic dissection
-
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
-
Patients undergoing invasive procedures as defined below:
- Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of bevacizumab or temsirolimus therapy
- Major surgical procedure anticipated during the course of the study.
- Minor surgical procedures, fine needle aspirates, or core biopsies within 7 days prior to the first date of study therapy
-
Patients with known prior history of interstitial pneumonitis
-
Patients with CTCAE v. 3, grade 2 or greater hypoxemia
-
Patients with CTCAE v. 3, grade 2 or greater dyspnea
-
Patients must not have uncontrolled diabetes, and must not have baseline hemoglobin A1C (HgbA1C) > 8
-
Patients with peripheral neuropathy > CTCAE v.3, grade 1
-
Patients who are pregnant or nursing
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Arm I (paclitaxel, carboplatin, bevacizumab)
Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. |
Given IV
Autres noms:
Given IV
Autres noms:
Correlative studies Given IV
Autres noms:
|
|
Expérimental: Arm II (paclitaxel, carboplatin, temsirolimus)
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. |
Given IV
Autres noms:
Given IV
Autres noms:
Correlative studies Given IV
Autres noms:
|
|
Expérimental: Arm III (ixabepilone, carboplatin, bevacizumab)
Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. |
Given IV
Autres noms:
Correlative studies Given IV
Autres noms:
Given IV
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants Who Progressed or Died by 25 Months From Enrollment
Délai: at 25 months
|
PFS (Progression free survival) is defined as the duration of time from date of study entry to time of progression or death, whichever occurs first. Patients with a status of alive, progression-free are censored at their date of last follow-up. To lessen the potential for bias in the progression evaluation times between treatment arms and historical controls, progression/death times will be grouped over 6 18-week time intervals. Progressions are carried forward to the end of the interval. All progressions or deaths occurring after the 6th 18-week interval are censored at 25 months for this analysis. Study NCT00977574 |
at 25 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fréquence et gravité de la toxicité évaluées par CTCAE v3.0 pour chacun des trois bras.
Délai: Médiane de 10 cycles de traitement plus 30 jours
|
Médiane de 10 cycles de traitement plus 30 jours
|
|
|
The Median Duration of Overall Survival for Each of the Three Arms.
Délai: Time from date of study entry to time of death or the date of last contact, assessed up to 5 years
|
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. |
Time from date of study entry to time of death or the date of last contact, assessed up to 5 years
|
|
The Proportion of Patients With Measurable Disease Who Have Confirmed Objective Tumor Responses by Treatment.
Délai: Imaging was done every 3 cycles and at any other time clinically indicated. Imaging was required every 9 weeks until progression or initiation on non protocol therapy. After 2 years of protocol therapy or follow up, CT scan or MRI was every 3 months
|
RECIST 1.1 was used to define objective tumor response. A complete response is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. A partial response is defined as At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. There can be no unequivocal progression of non-target lesions and no new lesions. Complete and partial responses are included in the objective tumor response rate. Confirmation of response was not required. |
Imaging was done every 3 cycles and at any other time clinically indicated. Imaging was required every 9 weeks until progression or initiation on non protocol therapy. After 2 years of protocol therapy or follow up, CT scan or MRI was every 3 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Carol Aghajanian, NRG Oncology
Publications et liens utiles
Publications générales
- Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Aghajanian C, Samuelson MI, Lankes HA, Soslow RA, Leslie KK. TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2022 Oct 1;40(28):3289-3300. doi: 10.1200/JCO.21.02506. Epub 2022 Jun 3.
- Leslie KK, Filiaci VL, Mallen AR, Thiel KW, Devor EJ, Moxley K, Richardson D, Mutch D, Secord AA, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Casablanca Y, Jackson A, Rose PG, Zhou X, McHale M, Lankes H, Levine DA, Aghajanian C. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 Apr;161(1):113-121. doi: 10.1016/j.ygyno.2021.01.025. Epub 2021 Feb 2.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Acides aminés, peptides et protéines
- Protéines
- Composés de soufre
- Produits chimiques organiques
- Hydrocarbures
- Cycloparaffines
- Hydrocarbures, alicyclique
- Hydrocarbures, cyclique
- Terpènes
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Produits chimiques inorganiques
- Complexes de coordination
- Taxes
- Cyclodécanes
- Diterpènes
- Économie et organisations des soins de santé
- Macrolides
- Lactones
- Isotypes d'immunoglobulines
- Sulfures
- Anions
- Ions
- Électrolytes
- Sulfure d'hydrogène
- Polycétides
- Économie
- Bévacizumab
- Sirolimus
- Carboplatine
- Paclitaxel
- Immunoglobuline G
- Épothilones
- Disulfures
- Temsirolimus
- ixabépilone
- Taxes
Autres numéros d'identification d'étude
- NCI-2011-01969
- U10CA180868 (Subvention/contrat des NIH des États-Unis)
- U10CA027469 (Subvention/contrat des NIH des États-Unis)
- NCI-2011-01969 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
- GOG-0086P (Autre identifiant: CTEP)
- CDR0000654472
- GOG-0086P
- GOG-0086P (Autre identifiant: NRG Oncology)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .